223 related articles for article (PubMed ID: 23334403)
21. The effect of CYP3A4*1G allele on the pharmacokinetics of atorvastatin in Chinese Han patients with coronary heart disease.
He BX; Shi L; Qiu J; Zeng XH; Zhao SJ
J Clin Pharmacol; 2014 Apr; 54(4):462-7. PubMed ID: 24214373
[TBL] [Abstract][Full Text] [Related]
22. Bioequivalence of fixed dose combination of atorvastatin 10 mg and aspirin 150 mg capsules: a randomized, open-label, single-dose, two-way crossover study in healthy human subjects.
Tippabhotla SK; Betha MR; Gadiko C; Battula R; Nakkawar M; Cheerla R; Khan SM; Yergude S; Thota S; Vobalaboina V
Drug Res (Stuttg); 2013 May; 63(5):250-7. PubMed ID: 23526241
[TBL] [Abstract][Full Text] [Related]
23. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of nifedipine in rats: Possible role of P-gp and CYP3A4 inhibition by HMG-CoA reductase inhibitors.
Lee CK; Choi JS; Choi DH
Pharmacol Rep; 2015 Feb; 67(1):44-51. PubMed ID: 25560574
[TBL] [Abstract][Full Text] [Related]
24. A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson's disease, and atorvastatin.
Rao N; Dvorchik B; Sussman N; Wang H; Yamamoto K; Mori A; Uchimura T; Chaikin P
J Clin Pharmacol; 2008 Sep; 48(9):1092-8. PubMed ID: 18552277
[TBL] [Abstract][Full Text] [Related]
25. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus.
Lemahieu WP; Hermann M; Asberg A; Verbeke K; Holdaas H; Vanrenterghem Y; Maes BD
Am J Transplant; 2005 Sep; 5(9):2236-43. PubMed ID: 16095503
[TBL] [Abstract][Full Text] [Related]
26. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.
Neuvonen PJ; Kantola T; Kivistö KT
Clin Pharmacol Ther; 1998 Mar; 63(3):332-41. PubMed ID: 9542477
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism.
Lau YY; Okochi H; Huang Y; Benet LZ
Drug Metab Dispos; 2006 Jul; 34(7):1175-81. PubMed ID: 16624870
[TBL] [Abstract][Full Text] [Related]
28. Disposition of atorvastatin, rosuvastatin, and simvastatin in oatp1b2-/- mice and intraindividual variability in human subjects.
DeGorter MK; Urquhart BL; Gradhand U; Tirona RG; Kim RB
J Clin Pharmacol; 2012 Nov; 52(11):1689-97. PubMed ID: 22167570
[TBL] [Abstract][Full Text] [Related]
29. Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers.
Aquilante CL; Wempe MF; Sidhom MS; Kosmiski LA; Predhomme JA
Eur J Clin Pharmacol; 2013 Jul; 69(7):1401-9. PubMed ID: 23407853
[TBL] [Abstract][Full Text] [Related]
30. A preliminary evaluation of neural network analysis for pharmacodynamic modeling of the dosing of the hydroxymethylglutaryl coenzyme A-reductase inhibitors simvastatin and atorvastatin.
Moon A; Smith T
Clin Ther; 2002 Apr; 24(4):653-61. PubMed ID: 12017409
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic and bioequivalence testing of atorvastatin formulations in healthy male volunteers.
Mendoza L; Hajdúch M; Plausinaitis R; Platílová V; Emritte N; Svoboda M
Pharmazie; 2006 Sep; 61(9):805-6. PubMed ID: 17020163
[TBL] [Abstract][Full Text] [Related]
32. Effects of SLCO1B1 and ABCB1 genotypes on the pharmacokinetics of atorvastatin and 2-hydroxyatorvastatin in healthy Korean subjects.
Lee YJ; Lee MG; Lim LA; Jang SB; Chung JY
Int J Clin Pharmacol Ther; 2010 Jan; 48(1):36-45. PubMed ID: 20040338
[TBL] [Abstract][Full Text] [Related]
33. Cimetidine does not alter atorvastatin pharmacokinetics or LDL-cholesterol reduction.
Stern RH; Gibson DM; Whitfield LR
Eur J Clin Pharmacol; 1998 Feb; 53(6):475-8. PubMed ID: 9551707
[TBL] [Abstract][Full Text] [Related]
34. ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin.
Keskitalo JE; Kurkinen KJ; Neuvoneni PJ; Niemi M
Clin Pharmacol Ther; 2008 Oct; 84(4):457-61. PubMed ID: 19238649
[TBL] [Abstract][Full Text] [Related]
35. Absence of pharmacokinetic and pharmacodynamic interactions between almorexant and warfarin in healthy subjects.
Dingemanse J; Hoever P
Drugs R D; 2013 Jun; 13(2):145-51. PubMed ID: 23737453
[TBL] [Abstract][Full Text] [Related]
36. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
Yang SH; Choi JS; Choi DH
Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429
[TBL] [Abstract][Full Text] [Related]
37. Erythromycin coadministration increases plasma atorvastatin concentrations.
Siedlik PH; Olson SC; Yang BB; Stern RH
J Clin Pharmacol; 1999 May; 39(5):501-4. PubMed ID: 10234598
[TBL] [Abstract][Full Text] [Related]
38. Systemic exposure to atorvastatin between Asian and Caucasian subjects: a combined analysis of 22 studies.
Gandelman K; Fung GL; Messig M; Laskey R
Am J Ther; 2012 May; 19(3):164-73. PubMed ID: 20975528
[TBL] [Abstract][Full Text] [Related]
39. effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers.
Lau YY; Huang Y; Frassetto L; Benet LZ
Clin Pharmacol Ther; 2007 Feb; 81(2):194-204. PubMed ID: 17192770
[TBL] [Abstract][Full Text] [Related]
40. Clinical pharmacokinetics of atorvastatin.
Lennernäs H
Clin Pharmacokinet; 2003; 42(13):1141-60. PubMed ID: 14531725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
